JP2004504802A - 骨粗鬆症の診断および療法 - Google Patents

骨粗鬆症の診断および療法 Download PDF

Info

Publication number
JP2004504802A
JP2004504802A JP2001520922A JP2001520922A JP2004504802A JP 2004504802 A JP2004504802 A JP 2004504802A JP 2001520922 A JP2001520922 A JP 2001520922A JP 2001520922 A JP2001520922 A JP 2001520922A JP 2004504802 A JP2004504802 A JP 2004504802A
Authority
JP
Japan
Prior art keywords
allele
activity
gene
protein
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001520922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004504802A5 (enExample
Inventor
ヴァン・ダイク，サイモン
ダフ，ゴードン・ダブリュー
Original Assignee
インターロイキン・ジェネティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターロイキン・ジェネティクス・インコーポレーテッド filed Critical インターロイキン・ジェネティクス・インコーポレーテッド
Publication of JP2004504802A publication Critical patent/JP2004504802A/ja
Publication of JP2004504802A5 publication Critical patent/JP2004504802A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001520922A 1999-08-30 2000-08-30 骨粗鬆症の診断および療法 Pending JP2004504802A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15146099P 1999-08-30 1999-08-30
PCT/US2000/023844 WO2001016377A2 (en) 1999-08-30 2000-08-30 Diagnostics and therapeutics for osteoporosis

Publications (2)

Publication Number Publication Date
JP2004504802A true JP2004504802A (ja) 2004-02-19
JP2004504802A5 JP2004504802A5 (enExample) 2007-04-12

Family

ID=22538869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001520922A Pending JP2004504802A (ja) 1999-08-30 2000-08-30 骨粗鬆症の診断および療法

Country Status (11)

Country Link
US (2) US6558905B1 (enExample)
EP (1) EP1212464B1 (enExample)
JP (1) JP2004504802A (enExample)
AT (1) ATE318328T1 (enExample)
AU (2) AU785040B2 (enExample)
BR (1) BR0014150A (enExample)
CA (1) CA2382848C (enExample)
DE (1) DE60026150T2 (enExample)
ES (1) ES2261239T3 (enExample)
MX (1) MXPA02002251A (enExample)
WO (1) WO2001016377A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508022A (ja) * 1999-06-30 2003-03-04 インターリューキン ジェネティックス インコーポレイテッド Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法
US20090023147A1 (en) * 1999-08-30 2009-01-22 Kenneth Kornman Diagnostics and therapeutics for osteoporosis
JP2005500032A (ja) * 2001-06-15 2005-01-06 インターリューキン ジェネティックス インコーポレイテッド 老化関連症状の早期発現を検出および治療する方法
TWI346700B (en) * 2002-01-25 2011-08-11 Interleukin Genetics Inc The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
AU2003265676A1 (en) * 2002-08-24 2004-03-11 Creighton University Methods for detecting genes associated with bone properties and/or height
JP2006516196A (ja) * 2003-01-16 2006-06-29 デコード ジェネティクス イーエッチエフ． ハプロタイプ関連に基づく、骨粗鬆症または骨粗鬆症に対する罹患性の診断方法
DE602004030367D1 (de) 2003-08-08 2011-01-13 Interleukin Genetics Inc Diagnostikum für osteoporose
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
RU2271827C1 (ru) * 2004-09-28 2006-03-20 Федеральное государственное учреждение"Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи Федерального агенства по здравоохранению и социальному развитию"(ФГУ "СПбНИИ ЛОР Росздрава") Способ определения тактики лечения рекомбинантным цитокином, регулирующим воспаление
US7353662B2 (en) * 2004-12-22 2008-04-08 York International Corporation Medium voltage starter for a chiller unit
US8590329B2 (en) 2004-12-22 2013-11-26 Johnson Controls Technology Company Medium voltage power controller
US8105775B2 (en) * 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US8101360B2 (en) * 2006-11-15 2012-01-24 Interleukin Genetics, Inc. IL-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same
WO2017123696A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
CA3142662A1 (en) 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044150A1 (en) * 1997-03-27 1998-10-08 Gemini Research Ltd. Polymorphisms of an il-1 receptor antagonist gene
WO1998054359A1 (en) * 1997-05-29 1998-12-03 Gordon Duff Prediction of inflammatory disease associated with il-1 geneloci polymorphisms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
CA1316520C (en) 1987-05-19 1993-04-20 Larry C. Hamilton Valve
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
WO1993011149A1 (en) 1991-12-03 1993-06-10 Thomas Jefferson University Methods of detecting a genetic predisposition for osteoporosis
WO1994003633A1 (en) 1992-07-31 1994-02-17 Garvan Institute Of Medical Research Assessment of trans-acting factors allelic variation
DE69333641T2 (de) 1992-12-28 2005-11-03 Baylink, David Jeston, Redlands Methode zur messung der knochenresorption
IL108947A0 (en) 1993-03-12 1994-06-24 Osteopharm Ltd Bone stimulating factor
CA2164498C (en) 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044150A1 (en) * 1997-03-27 1998-10-08 Gemini Research Ltd. Polymorphisms of an il-1 receptor antagonist gene
WO1998054359A1 (en) * 1997-05-29 1998-12-03 Gordon Duff Prediction of inflammatory disease associated with il-1 geneloci polymorphisms

Also Published As

Publication number Publication date
AU2006203097A1 (en) 2006-08-17
AU785040B2 (en) 2006-08-31
EP1212464B1 (en) 2006-02-22
ES2261239T3 (es) 2006-11-16
WO2001016377A2 (en) 2001-03-08
US20040110168A1 (en) 2004-06-10
AU2006203097B2 (en) 2009-03-12
WO2001016377A3 (en) 2002-01-17
US6558905B1 (en) 2003-05-06
MXPA02002251A (es) 2003-08-20
CA2382848C (en) 2011-01-04
DE60026150D1 (de) 2006-04-27
ATE318328T1 (de) 2006-03-15
AU7338000A (en) 2001-03-26
EP1212464A2 (en) 2002-06-12
DE60026150T2 (de) 2006-11-16
CA2382848A1 (en) 2001-03-08
BR0014150A (pt) 2002-05-14

Similar Documents

Publication Publication Date Title
US20020146700A1 (en) Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
US20090163460A1 (en) Diagnostics and therapeutics for early-onset menopause
US20100279280A1 (en) Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US6558905B1 (en) Diagnostics and therapeutics for osteoporosis
US20080254477A1 (en) il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
WO2001016377A9 (en) Diagnostics and therapeutics for osteoporosis
US7723028B2 (en) Diagnostics and therapeutics for osteoporosis
AU778975B2 (en) Therapeutics and diagnostics based on an IL-1B mutation
US20090023147A1 (en) Diagnostics and therapeutics for osteoporosis
US8105775B2 (en) IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US20040171038A1 (en) IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US20080118920A1 (en) Diagnostics And Therapeutics For Diseases Associated With An Il-1 Inflammatory Haplotype
CA2565562A1 (en) Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype
HK1093757B (en) Diagnostic for osteoporosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100331

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110601

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130222